Whalesbook
AI Healthcare Mein New Investment!
Latent View Analytics ki subsidiary ne US-based Healtheon AI Inc. mein $3 Million ka strategic investment kiya hai. Ye move healthcare sector mein AI capabilities ko badhane ke liye hai, khaas kar Revenue Cycle Management (RCM) ke liye. Healtheon AI-driven solutions banati hai, aur Latent View iss field mein apna stake badhana chahti hai.
Stock Mein Toofani Tezi!
Is investment ki khabar sunte hi Latent View Analytics ka stock Thursday, April 2, 2026 ko 9% tak upar bhaga! Intraday mein ₹284.50 ka high banaya aur 11:15 AM tak ₹282.85 par trade kar raha tha, jo pichhle din se 8.3% zyada hai. Yeh rally tab hui jab market mein overall thodi mandi thi aur NSE Nifty 50 2% neeche tha. Investment Simple Agreement for Future Equity (SAFE) notes ke through ki gayi hai.
Valuation Aur Analysts Kya Kehte Hain?
Haan, stock aaj tez hua hai, par saal ke hisaab se dekhein toh Latent View Analytics 38% neeche hai. Iska P/E ratio March/April 2026 mein 27.19x se 34.0x ke beech tha, jo Indian Professional Services industry ke average 20x se kaafi upar hai. Par Indian IT aur data analytics sector mein AI ki wajah se growth toh acchi hai, 27.48% CAGR expected hai 2025-2035 tak. Latent View ki Data Engineering mein partnerships (Databricks, Snowflake, GCP) achhi hain. Q4 FY25 mein revenue 21.89% badhkar ₹295.62 Cr aur profit 19.67% badhkar ₹50.14 Cr hua tha. Lekin Q2 FY26 mein margins par pressure dikha tha.
Brokerage Ki Rai Aur Price Targets
Brokerage firm PL Capital ne toh 'Buy' rating maintain ki hai, unhe Latent View ki AI opportunities dikh rahi hain. Lekin unhone FY27 aur FY28 ke liye USD revenue estimates kam kar diye hain aur target price ko ₹630 se ghatakar ₹490 kar diya hai (32x P/E multiple par). PL Capital ko Diagnostics segment mein AI se thoda pressure lag raha hai (jo unke revenue ka 60% hai), par Data Engineering mein growth ki ummeed hai. Analyst consensus price targets average ₹513.83 ke aas-paas hain.
Abhi Bhi Concerns Hain!
Itni rally ke baad bhi kuch chintaayein bani hui hain. Stock saal bhar mein 38% neeche hai, matlab market ko abhi bhi poori tarah bharosa nahi hai. Valuation bhi premium lag raha hai. PL Capital ki kam hui revenue estimates aur target price bhi heads-up de rahe hain. Hi-Tech aur Diagnostics segments mein pressure ho sakta hai. Competition bhi kaafi hai bade players jaise TCS aur Infosys se.
Future Outlook Aur Risks
Latent View Analytics par koi debt nahi hai, par return on equity pichhle teen saalon mein 12.4% raha hai, jo kam hai. Healtheon AI investment strategic toh hai, par startup hone ke naate execution aur integration risks ho sakte hain. Healtheon ke baare mein thodi mixed reports hain ki woh kab incorporate hui aur uski current status kya hai. Latent View ke Q2 FY26 results bhi revenue growth ke bawajood declining profitability aur margin compression dikha rahe the.
Aage Kya Plan Hai?
Company ka plan hai AI aur Agentic AI frameworks ko scale karna, taaki woh ek AI consultant ke roop mein strong ho sake. U.S. healthcare RCM mein AI-enabled applications par focus rahega. Analysts overall positive hain aur 'Buy' ratings de rahe hain. Management FY26 mein high-teens revenue growth aur stable margins ki ummeed kar raha hai, jo AI Center of Excellence (CoE) aur Databricks mein investments se aayegi.